Johnson & Johnson’s stock jumped 8 percent Monday when news broke that the company will begin human clinical testing for a COVID-19 vaccine by September and that it has secured a $1 billion deal with the U.S. government as it races to produce more than a billion doses by the end of next year. Dr. Paul Stoffels, Chief Scientific Officer at Johnson & Johnson, told Cheddar on Tuesday that he’s confident the company will have a vaccine ready for testing within the next few months.